Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study observed that patients with burning mouth syndrome had higher levels of cystatin SN in resting saliva compared to healthy controls, suggesting a potential biomarker for the condition.

This study reported that six out of seven pediatric patients with refractory patchy alopecia areata experienced significant hair regrowth after one month of oral tofacitinib treatment, suggesting it may be an effective and safe option, although larger studies are needed to evaluate long-term safety.

This study suggests testosterone gel administered for one year to male chronic pain patients receiving morphine may improve sexual function and mental health, despite limited effects on overall pain scores.

This study found that cyclosporin helped manage symptoms in about half of the cats with pruritus and eosinophilic dermatoses, though overall scores did not significantly improve.

This study found that both Diane 35 plus spironolactone and Diane 35 plus finasteride were equally effective and safe for treating hirsutism and acne in Indian women over a 12-month period.

In this study, Buserelin nasal spray significantly reduced hirsutism scores and suppressed ovarian steroid secretion in women with non-adrenal hirsutism over six months, with effects lasting post-treatment.

This study found that Baricitinib effectively reduced alopecia severity in adults with severe alopecia areata during a 12-month observation period, especially when initiated in patients with milder baseline conditions and elevated ESR; no serious adverse events were reported.

This study compared oral tofacitinib and methotrexate in treating moderate-to-severe alopecia areata, finding that tofacitinib was more effective at reducing SALT scores and improving scalp hair assessment PRO scores, though both treatments reduced psychological distress similarly without serious adverse effects.

This study found that minoxidil sulfate enhanced hair growth in CRF-OE mice, with increased hair growth scores observed at 2 and 4 weeks after treatment.

This study found that platelet-rich plasma injections for vocal fold scarring and atrophy showed a favorable safety profile and subjective improvements in vocal quality and fatigue over a three-month follow-up.

This study found that tofacitinib effectively induced hair regrowth in 62.2% of severe alopecia areata patients in Saudi Arabia after six months, with higher baseline Severity of Alopecia Tool scores and past steroid use linked to reduced response.

In this study, daily treatment with ritlecitinib for up to 24 months led to significant reductions in high-severity alopecia areata SALT scores among patients aged ≥12 years, including those with severe forms such as alopecia totalis and universalis.

This study found that oral baricitinib was more effective than methotrexate in treating severe alopecia areata, with significant improvements in SALT scores over six months.

This study found that Plinest injections improved skin hydration and elasticity in the face, neck, and décolleté and were well-tolerated, with high patient satisfaction over a 4-month follow-up.

This study found that applying 5% topical minoxidil gel on treatment-resistant vitiligo patches may promote early repigmentation, showing significant improvement at one month compared to a placebo, though later differences were not statistically significant.

This study found that the combination of PRP with topical minoxidil and finasteride showed the most significant improvement in hair pull tests and patient satisfaction for male androgenetic alopecia, surpassing individual therapies and placebo over a six-month period.

In this pilot study, researchers found that fractional picosecond laser therapy may promote hair regrowth in men with mild-to-moderate androgenetic alopecia, with significant improvements in expert assessments and patient satisfaction observed over a four-month period, though further research is needed to confirm these findings.

This study found that both finasteride and low level laser therapy were similarly effective in improving hair regrowth for frontal pattern hair loss in men and women over a 3-month period.

This study conducted in Peshawar, Pakistan, observed that individuals with Long COVID frequently reported systemic symptoms such as hair loss, headache, and fatigue, along with oral issues like loss of taste and dry mouth, highlighting the importance of incorporating oral symptom assessments in post-COVID care.

This study found that metformin therapy is associated with the initiation of ovulatory cycles in women with PCOS and a trend toward reduced 17P responses after six months, but did not improve hirsutism or body composition.

This study suggests that hydroxychloroquine may benefit some children with alopecia areata, as five out of nine patients showed improvement, although side effects like gastrointestinal intolerance and headache were noted.

This conceptual paper proposes evaluating the Ayurvedic formulation Moorvadi choornam for alleviating side effects of chemotherapy, including symptoms consistent with Garavisha lakshanas, but reports no clinical outcomes.

This study found that flutamide was more effective than spironolactone in reducing symptoms of hirsutism and related conditions in premenopausal women, with fewer discontinuations due to side effects.

This study found that a low dose of flutamide, both alone and combined with an oral contraceptive, effectively reduced hirsutism in women, with the combination showing more lasting effects post-treatment.

This study found that long-term finasteride therapy in men with BPH worsened erectile dysfunction and reduced testosterone levels, while these effects were not observed with tamsulosin.

This study found that three months of metformin therapy improved acne, hirsutism, and menstrual irregularities in women with PCOS, along with hormonal and ultrasonographic changes.

This study found that after 15 months of treatment with ritlecitinib, patients with alopecia areata and less than 95% initial hair loss experienced significant hair regrowth, though those with more extensive hair loss showed more variable improvement.

This randomized prospective study found that microneedling combined with autologous platelet-rich plasma resulted in significant hair regrowth and reduction in SALT score after 12 weeks in patients with chronic and stable alopecia areata, suggesting it as a safe and efficient treatment option.

In this retrospective case series, researchers observed that a combined treatment protocol of homoeopathy, Xogen therapy, diet, and vitamin supplementation progressively reduced hair fall and improved hair density in five male patients with androgenic alopecia.

This study found that both tofacitinib and methotrexate effectively reduced hair loss and psychological distress in patients with moderate-to-severe alopecia areata, but tofacitinib showed much greater efficacy. Both treatments had similar safety profiles, with no serious adverse effects reported.